Brian Yoor - Abbott Laboratories President
ABT Stock | USD 105.27 0.63 0.59% |
President
Mr. Brian B. Yoor serves as Chief Financial Officer, Executive Vice President Finance of the Company. Brian joined Abbott in August 1997, and held various financial management positions of increasing responsibility, including Controller positions in the pharmaceutical, nutrition, and diagnostic businesses, before being asked to lead Abbotts Investor Relations effort in January 2013. He became Abbotts Chief Financial Officer in June 2015. Prior to joining Abbott, Brian was a certified public accountant with Arthur Andersen and held financial positions in the consumer industry with the Scotts Company and Newell Rubbermaid. In Abbott Finance, we are the stewards that enable financial reliability and growth for Abbott, says Brian. A strong, growing company is better able to help people around the world live their healthiest lives. Brian serves on the board of the Clara Abbott Foundation. He is a member of the CNBC Global CFO Council. He earned his bachelors degree in accounting at the University of Toledo in Ohio. since 2017.
Age | 48 |
Tenure | 7 years |
Address | 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400 |
Phone | 224 667 6100 |
Web | https://www.abbott.com |
Abbott Laboratories Management Efficiency
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.Similar Executives
Showing other executives | PRESIDENT Age | ||
Maulik Nanavaty | Boston Scientific Corp | ||
Michael Crowley | Bio Rad Laboratories | 62 | |
David Pierce | Boston Scientific Corp | 57 | |
Andrew Last | Bio Rad Laboratories | 64 | |
John Sorenson | Boston Scientific Corp | 56 | |
Giovanni Magni | Bio Rad Laboratories | 63 | |
Keith Dawkins | Boston Scientific Corp | 65 | |
Richard Kuntz | Medtronic PLC | 63 | |
Robert White | Medtronic PLC | 61 | |
Hooman Hakami | Medtronic PLC | 48 | |
Ian Meredith | Boston Scientific Corp | 64 | |
Supratim Bose | Boston Scientific Corp | 63 | |
Julie Signorille | Paragon 28 | 50 | |
Joseph Saffire | Paragon 28 | 44 | |
Geoffrey Martha | Medtronic PLC | 54 | |
Eddie Oliveira | Establishment Labs Holdings | 35 | |
Joseph Fitzgerald | Boston Scientific Corp | 60 | |
Jodi Eddy | Boston Scientific Corp | 50 | |
Warren Wang | Boston Scientific Corp | 44 | |
Eric Thepaut | Boston Scientific Corp | 59 | |
RICHARD BARRY | Paragon 28 | 48 |
Management Performance
Return On Equity | 0.15 | ||||
Return On Asset | 0.0611 |
Abbott Laboratories Leadership Team
Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Samuel Scott, Independent Director | ||
Christopher Scoggins, Senior Vice President - Rapid Diagnostics | ||
Roger Bird, Senior Vice President - U.S. Nutrition | ||
Michael Dale, Senior Vice President - Structural Heart | ||
Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
Heather Mason, Senior Vice President - Abbott Diabetes Care | ||
James Farrell, Independent Director | ||
Phebe Novakovic, Independent Director | ||
JeanYves Pavee, Senior Vice President - Established Pharmaceuticals, Developed Markets | ||
Roxanne Austin, Independent Director | ||
Stephen Fussell, Executive Vice President - Human Resources | ||
Sally Blount, Independent Director | ||
Daniel Starks, Independent Director | ||
Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure | ||
Thomas Frinzi, Senior Vice President - Abbott Medical Optics | ||
Lisa Earnhardt, Executive Vice President - Medical Devices | ||
Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America | ||
Robert Alpern, Independent Director | ||
Murthy Simhambhatla, Senior Vice President - Abbott Medical Optics | ||
Glenn Tilton, Independent Director | ||
Darren McDew, Independent Director | ||
Christopher Calamari, Senior Vice President - U.S. Nutrition | ||
Erica Battaglia, VP Officer | ||
Richard Ashley, Executive VP of Corporate Devel. | ||
Michael Rousseau, President - Cardiovascular and Neuromodulation | ||
Charles Brynelsen, Senior Vice President - Abbott Vascular | ||
Hubert Allen, Executive Vice President, General Counsel, Secretary | ||
Charles Foltz, Senior Vice President - Abbott Vascular | ||
Brian Yoor, Chief Financial Officer, Executive Vice President - Finance | ||
Gregory Ahlberg, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | ||
Philip Boudreau, Vice President - Finance, Controller | ||
John Ginascol, Executive Vice President - Core Diagnostics | ||
Patricia Gonzalez, Independent Director | ||
Jared Watkin, Senior Vice President - Diabetes Care | ||
Brian Blaser, Executive VP of Diagnostic Products | ||
Scott White, Senior Vice President - International Nutrition | ||
Michael Roman, Independent Director | ||
Deepak Nath, Senior Vice President - Abbott Vascular | ||
Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | ||
Mary Moreland, Executive Vice President of Human Resources | ||
Nancy McKinstry, Independent Director | ||
Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
Sabina Ewing, Senior Officer | ||
Georges Vos, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
Thomas Freyman, Executive VP of Fin. and Admin. | ||
Randel Woodgrift, Senior Vice President - CRM | ||
Michelle Kumbier, Independent Director | ||
Eric Fain, Senior Vice President Group President - Cardiovascular and Neuromodulation | ||
John Capek, Executive Vice President - Ventures | ||
Miles White, Chairman, CEO and Chairman of Executive Committee | ||
Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director | ||
Elaine Leavenworth, VP Officer | ||
Edward Liddy, Independent Director | ||
John Stratton, Independent Director | ||
Joseph Manning, Senior Vice President - Abbott Nutrition International | ||
Scott Leinenweber, Acquisitions Licensing | ||
James Young, VP Officer | ||
William Osborn, Lead Independent Director | ||
Michael Warmuth, Executive Vice President - Established Pharmaceuticals | ||
Louis Morrone, Senior Vice President - Rapid Diagnostics | ||
Robert Funck, Chief Financial Officer, Executive Vice President - Finance | ||
Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America. | ||
Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics | ||
Melissa Brotz, Vice Marketing |
Abbott Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.15 | ||||
Return On Asset | 0.0611 | ||||
Profit Margin | 0.14 % | ||||
Operating Margin | 0.20 % | ||||
Current Valuation | 198.32 B | ||||
Shares Outstanding | 1.74 B | ||||
Shares Owned By Insiders | 0.53 % | ||||
Shares Owned By Institutions | 77.01 % | ||||
Number Of Shares Shorted | 14.48 M | ||||
Price To Earning | 24.14 X |
Abbott Laboratories Investors Sentiment
The influence of Abbott Laboratories' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Abbott. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Abbott Laboratories' public news can be used to forecast risks associated with an investment in Abbott. The trend in average sentiment can be used to explain how an investor holding Abbott can time the market purely based on public headlines and social activities around Abbott Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Abbott Laboratories' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Abbott Laboratories' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Abbott Laboratories' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Abbott Laboratories.
Abbott Laboratories Implied Volatility | 89.57 |
Abbott Laboratories' implied volatility exposes the market's sentiment of Abbott Laboratories stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Abbott Laboratories' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Abbott Laboratories stock will not fluctuate a lot when Abbott Laboratories' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Abbott Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Abbott Laboratories' short interest history, or implied volatility extrapolated from Abbott Laboratories options trading.
Pair Trading with Abbott Laboratories
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.Moving against Abbott Stock
0.44 | WST | West Pharmaceutical Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Abbott Stock analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Abbott Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbott Laboratories. If investors know Abbott will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbott Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.55 | Dividend Share 2.08 | Earnings Share 3.27 | Revenue Per Share 23.051 | Quarterly Revenue Growth 0.015 |
The market value of Abbott Laboratories is measured differently than its book value, which is the value of Abbott that is recorded on the company's balance sheet. Investors also form their own opinion of Abbott Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Abbott Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbott Laboratories' market value can be influenced by many factors that don't directly affect Abbott Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abbott Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.